COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

WY Chi, YD Li, HC Huang, TEH Chan, SY Chow… - Journal of biomedical …, 2022 - Springer
Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …

COVID-19, myocarditis and pericarditis

DL Fairweather, DJ Beetler, DN Di Florio… - Circulation …, 2023 - Am Heart Assoc
Viral infections are a leading cause of myocarditis and pericarditis worldwide, conditions that
frequently coexist. Myocarditis and pericarditis were some of the early comorbidities …

Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine: a case–control study

FTT Lai, X Li, K Peng, L Huang, P Ip, X Tong… - Annals of internal …, 2022 - acpjournals.org
Background: Case reports of carditis after BNT162b2 vaccination are accruing worldwide.
Objective: To examine the association of BNT162b2 and CoronaVac (Sinovac) vaccination …

Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children

A Dionne, F Sperotto, S Chamberlain, AL Baker… - JAMA …, 2021 - jamanetwork.com
Importance The BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine was
authorized on May 10, 2021, for emergency use in children aged 12 years and older. Initial …

[HTML][HTML] COVID-19 vaccine safety in adolescents aged 12–17 years—United States, December 14, 2020–July 16, 2021

AM Hause - MMWR. Morbidity and mortality weekly report, 2021 - cdc.gov
COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14,
2020–July 16, 2021 | MMWR Skip directly to site content Skip directly to search Español | Other …

Cardiovascular disease and COVID-19: a consensus paper from the ESC working group on coronary pathophysiology & microcirculation, ESC working group on …

E Cenko, L Badimon, R Bugiardini… - Cardiovascular …, 2021 - academic.oup.com
The cardiovascular system is significantly affected in coronavirus disease-19 (COVID-19).
Microvascular injury, endothelial dysfunction, and thrombosis resulting from viral infection or …

[HTML][HTML] Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging

HN Jung, SY Lee, S Lee, H Youn, HJ Im - Theranostics, 2022 - ncbi.nlm.nih.gov
Lipid nanoparticles (LNPs) have been one of the most successful nano-delivery vehicles
that enable efficient delivery of cytotoxic chemotherapy agents, antibiotics, and nucleic acid …

Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus …

B Heidecker, N Dagan, R Balicer… - European journal of …, 2022 - Wiley Online Library
Over 10 million doses of COVID‐19 vaccines based on RNA technology, viral vectors,
recombinant protein, and inactivated virus have been administered worldwide. Although …

Cardiac complications following mRNA COVID‐19 vaccines: A systematic review of case reports and case series

A Fazlollahi, M Zahmatyar, M Noori… - Reviews in medical …, 2022 - Wiley Online Library
There have been several local and systemic adverse events associated with mRNA COVID‐
19 vaccines. Pericarditis, myocarditis and myocardial infarction are examples of cardiac …

Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following comirnaty vaccination

GT Chua, MYW Kwan, CSL Chui… - Clinical Infectious …, 2022 - academic.oup.com
Background Age-specific incidence of acute myocarditis/pericarditis in adolescents following
Comirnaty vaccination in Asia is lacking. This study aimed to study the clinical characteristics …